Engineering virus-like particles as vaccine platforms

Current Opinion in Virology

Volumn 18, Issue , 2016, Pages 44-49

  Frietze, Kathryn M ^a   Peabody, David S ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; VIRUS LIKE PARTICLE VACCINE; VIRUS ANTIGEN;

ARTICLE; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS LIKE AGENT; CHEMISTRY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; PROCEDURES; VACCINE IMMUNOGENICITY;

ANTIGENS, VIRAL; GENETIC ENGINEERING; IMMUNOGENICITY, VACCINE; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84961933419     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.03.001     Document Type: Review

References (55)

1. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M.F. Bachmann Nanoparticles target distinct dendritic cell populations according to their size Eur J Immunol 38 2008 1404 1413
2. A. Link, F. Zabel, Y. Schnetzler, A. Titz, F. Brombacher, and M.F. Bachmann Innate immunity mediates follicular transport of particulate but not soluble protein antigen J Immunol 188 2012 3724 3733
3. F. Zabel, T.M. Kündig, and M.F. Bachmann Virus-induced humoral immunity: On how B cell responses are initiated Curr Opin Virol 3 2013 357 362
4. M.F. Bachmann, and G.T. Jennings Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns Nat Rev Immunol 10 2010 787 796
5. G.T. Jennings, and M.F. Bachmann The coming of age of virus-like particle vaccines Biol Chem 389 2008 521 536
6. M.F. Bachmann, and R.M. Zinkernagel Neutralizing antiviral B cell responses Annu Rev Immunol 15 1997 235 270
7. B. Chackerian, M.R. Durfee, and J.T. Schiller Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model J Immunol 180 2008 5816 5825
8. M.F. Bachmann, U.H. Rohrer, T.M. Kündig, K. Bürki, H. Hengartner, and R.M. Zinkernagel The influence of antigen organization on B cell responsiveness Science 262 1993 1448 1451
9. D.C. Whitacre, B.O. Lee, and D.R. Milich Use of hepadnavirus core proteins as vaccine platforms Expert Rev Vaccines 8 2009 1565 1573
10. J.N. Billaud, D. Peterson, M. Barr, A. Chen, M. Sallberg, F. Garduno, P. Goldstein, W. McDowell, J. Hughes, J. Jones, and et al. Combinatorial approach to hepadnavirus-like particle vaccine design J Virol 79 2005 13656 13666
11. J.C. Caldeira, and D.S. Peabody Thermal stability of RNA phage virus-like particles displaying foreign peptides J Nanobiotechnol 9 2011 22
12. D.S. Peabody Subunit fusion confers tolerance to peptide insertions in a virus coat protein Arch Biochem Biophys 347 1997 85 92
13. P. Plevka, K. Tars, and L. Liljas Structure and stability of icosahedral particles of a covalent coat protein dimer of bacteriophage MS2 Protein Sci 18 2009 1653 1661
14. D.S. Peabody, B. Manifold-Wheeler, A. Medford, S.K. Jordan, J. do Carmo Caldeira, and B. Chackerian Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2 J Mol Biol 380 2008 252 263
15. A.C. Tissot, P. Maurer, J. Nussberger, R. Sabat, T. Pfister, S. Ignatenko, H.D. Volk, H. Stocker, P. Muller, G.T. Jennings, and et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study Lancet 371 2008 821 827
16. P.M. Ambühl, A.C. Tissot, A. Fulurija, P. Maurer, J. Nussberger, R. Sabat, V. Nief, C. Schellekens, K. Sladko, K. Roubicek, and et al. A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity J Hypertens 25 2007 63 72
17. L. Klimek, J. Willers, A. Hammann-Haenni, O. Pfaar, H. Stocker, P. Mueller, W.A. Renner, and M.F. Bachmann Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: A phase IIb study Clin Exp Allergy 41 2011 1305 1312
18. D.S. Peabody A viral platform for chemical modification and multivalent display J Nanobiotechnol 1 2003 5
19. A. Chatterji, W.F. Ochoa, M. Paine, B.R. Ratna, J.E. Johnson, and T. Lin New addresses on an addressable virus nanoblock; uniquely reactive Lys residues on cowpea mosaic virus Chem Biol 11 2004 855 863
20. A. Servid, P. Jordan, A. O'Neil, P. Prevelige, and T. Douglas Location of the bacteriophage P22 coat protein C-terminus provides opportunities for the design of capsid-based materials Biomacromolecules 14 2013 2989 2995
21. L. Schoonen, J. Pille, A. Borrmann, R.J. Nolte, and J.C. van Hest Sortase A-mediated N-terminal modification of cowpea chlorotic mottle virus for highly efficient cargo loading Bioconjug Chem 2015
22. T. Koho, T.O. Ihalainen, M. Stark, H. Uusi-Kerttula, R. Wieneke, R. Rahikainen, V. Blazevic, V. Marjomäki, R. Tampé, M.S. Kulomaa, and et al. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display Eur J Pharm Biopharm 96 2015 22 31
23. K.G. Patel, and J.R. Swartz Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry Bioconjug Chem 22 2011 376 387
24. P.A. Venter, A. Dirksen, D. Thomas, M. Manchester, P.E. Dawson, and A. Schneemann Multivalent display of proteins on viral nanoparticles using molecular recognition and chemical ligation strategies Biomacromolecules 12 2011 2293 2301
25. S. Thrane, C.M. Janitzek, M. Agerbæk, S.B. Ditlev, M. Resende, M.A. Nielsen, T.G. Theander, A. Salanti, and A.F. Sander A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA PLOS ONE 10 2015 e0143071
26. K.D. Brune, D.B. Leneghan, I.J. Brian, A.S. Ishizuka, M.F. Bachmann, S.J. Draper, S. Biswas, and M. Howarth Plug-and-display: Decoration of virus-like particles via isopeptide bonds for modular immunization Sci Rep 6 2016 19234
27. T. Storni, F. Lechner, I. Erdmann, T. Bächi, A. Jegerlehner, T. Dumrese, T.M. Kündig, C. Ruedl, and M.F. Bachmann Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles J Immunol 168 2002 2880 2886
28. G.G. Pickett, and D.S. Peabody Encapsidation of heterologous RNAs by bacteriophage MS2 coat protein Nucleic Acids Res 21 1993 4621 4630
29. E. Tumban, J. Peabody, D.S. Peabody, and B. Chackerian A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvants Vaccine 31 2013 4647 4654
30. A. Jegerlehner, P. Maurer, J. Bessa, H.J. Hinton, M. Kopf, and M.F. Bachmann TLR9 signaling in B cells determines class switch recombination to IgG2a J Immunol 178 2007 2415 2420
31. K. Schwarz, E. Meijerink, D.E. Speiser, A.C. Tissot, I. Cielens, R. Renhof, A. Dishlers, P. Pumpens, and M.F. Bachmann Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles Eur J Immunol 35 2005 816 821
32. S. Carmicle, N.K. Steede, and S.J. Landry Antigen three-dimensional structure guides the processing and presentation of helper T-cell epitopes Mol Immunol 44 2007 1159 1168
33. K. Jemon, V. Young, M. Wilson, S. McKee, V. Ward, M. Baird, S. Young, and M. Hibma An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy PLOS ONE 8 2013 e66866
34. J.D. Fiedler, C. Higginson, M.L. Hovlid, A.A. Kislukhin, A. Castillejos, F. Manzenrieder, M.G. Campbell, N.R. Voss, C.S. Potter, B. Carragher, and et al. Engineered mutations change the structure and stability of a virus-like particle Biomacromolecules 13 2012 2339 2348
35. A.E. Ashcroft, H. Lago, J.M. Macedo, W.T. Horn, N.J. Stonehouse, and P.G. Stockley Engineering thermal stability in RNA phage capsids via disulphide bonds J Nanosci Nanotechnol 5 2005 2034 2041
36. Y. Lu, W. Chan, B.Y. Ko, C.C. VanLang, and J.R. Swartz Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery Proc Natl Acad Sci U S A 112 2015 12360 12365
37. E. Tumban, P. Muttil, C.A. Escobar, J. Peabody, D. Wafula, D.S. Peabody, and B. Chackerian Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2 Vaccine 33 2015 3346 3353
38. R. Lang, G. Winter, L. Vogt, A. Zurcher, B. Dorigo, and B. Schimmele Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation Drug Dev Ind Pharm 35 2009 83 97
39. P.A. Kratz, B. Böttcher, and M. Nassal Native display of complete foreign protein domains on the surface of hepatitis B virus capsids Proc Natl Acad Sci U S A 96 1999 1915 1920
40. A.C. Tissot, R. Renhofa, N. Schmitz, I. Cielens, E. Meijerink, V. Ose, G.T. Jennings, P. Saudan, P. Pumpens, and M.F. Bachmann Versatile virus-like particle carrier for epitope based vaccines PLoS ONE 5 2010 e9809
41. G. Spohn, C. Schori, I. Keller, K. Sladko, C. Sina, R. Guler, K. Schwarz, P. Johansen, G.T. Jennings, and M.F. Bachmann Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes Mol Ther Methods Clin Dev 1 2014 14048
42. H. Joshi, S. Cheluvaraja, E. Somogyi, D.R. Brown, and P. Ortoleva A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: A possible indicator of immunogenicity Vaccine 29 2011 9423 9430
43. H. Joshi, A. Singharoy, Y.V. Sereda, S.C. Cheluvaraja, and P.J. Ortoleva Multiscale simulation of microbe structure and dynamics Prog Biophys Mol Biol 107 2011 200 217
44. H. Joshi, K. Lewis, A. Singharoy, and P.J. Ortoleva Epitope engineering and molecular metrics of immunogenicity: A computational approach to VLP-based vaccine design Vaccine 31 2013 4841 4847
45. E. Crossey, K. Frietze, D.L. Narum, D.S. Peabody, and B. Chackerian Identification of an immunogenic mimic of a conserved epitope on the Plasmodium falciparum blood stage antigen AMA1 using virus-like particle (VLP) peptide display PLOS ONE 10 2015 e0132560
46. L. Zhang, R. Tang, S. Bai, N.K. Connors, L.H. Lua, Y.P. Chuan, A.P. Middelberg, and Y. Sun Energetic changes caused by antigenic module insertion in a virus-like particle revealed by experiment and molecular dynamics simulations PLOS ONE 9 2014 e107313
47. N.P. King, J.B. Bale, W. Sheffler, D.E. McNamara, S. Gonen, T. Gonen, T.O. Yeates, and D. Baker Accurate design of co-assembling multi-component protein nanomaterials Nature 510 2014 103 108
48. P. Burkhard, and D.E. Lanar Malaria vaccine based on self-assembling protein nanoparticles Expert Rev Vaccines 14 2015 1525 1527
49. R.L. Ord, J.C. Caldeira, M. Rodriguez, A. Noe, B. Chackerian, D.S. Peabody, G. Gutierrez, and C.A. Lobo A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein Malar J 13 2014 326
50. J. Caldeira, J. Bustos, J. Peabody, B. Chackerian, and D.S. Peabody Epitope-specific anti-hCG vaccines on a virus like particle platform PLOS ONE 10 2015 e0141407
51. B. Chackerian, C. Caldeira Jdo, J. Peabody, and D.S. Peabody Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles J Mol Biol 409 2011 225 237
52. C. Caldeira Jdo, A. Medford, R.C. Kines, C.A. Lino, J.T. Schiller, B. Chackerian, and D.S. Peabody Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7 Vaccine 28 2010 4384 4393
53. K.M. Frietze, R.B. Roden, J.H. Lee, Y. Shi, D.S. Peabody, and B. Chackerian Identification of anti-CA125 antibody responses in ovarian cancer patients by a novel deep sequence-coupled biopanning platform Cancer Immunol Res 2015
54. J.P. O'Rourke, D.S. Peabody, and B. Chackerian Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform Curr Opin Virol 11 2015 76 82
55. L.A. Kelley, S. Mezulis, C.M. Yates, M.N. Wass, and M.J. Sternberg The Phyre2 web portal for protein modeling, prediction and analysis Nat Protoc 10 2015 845 858